GW Pharmaceuticals plc GWPH Epidiolex drug and earlier-stage programs Sativex and CBDV will represent major catalysts for the stock in the near-term, in Cantor Fitzgerald's view.
The Analyst
Analyst Elemer Piros reiterated an Overweight on GW Pharmaceuticals with a $211 price target.
The Thesis
Cantor's thesis is focused on Epidiolex. Since its Nov. 1 launch, Epidiolex is seeing strong demand in the U.S., Piros said in a Tuesday note. (See his track record here.)
In Europe, where Epidiolex is awaiting approval from the EMA, GW has already launched marketing campaigns in five major markets, the analyst said.
Epidiolex has shown strong results in the second study of the drug in Dravet Syndrome, Piros said.
Cantor Fitzgerald estimated the company's fair value by calculating the risk-adjusted cash flow for Epidiolex. Cantor's estimates imply a UK tax rate of 21 percent and a 15-percent discount rate, which results in a sum of risk-adjusted NPV for Epidiolex of around $5.1 billion.
Cantor added $500 million for the drug portfolio and $348 million in cash, obtaining a total value for the company of $6 billion, or $211 per ADS.
Price Action
GW Pharmaceuticals shares were down 1.36 percent at $120.07 at the time of publication Wednesday.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.